Moderate
Suspected
Descripción
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.
Mecanismo
Duloxetine inhibits both SERT and NET; sumatriptan activates 5-HT1B/1D receptors, producing overlapping serotonergic stimulation.
Relevancia clínica
FDA labeling for triptans warns of serotonin syndrome risk when combined with serotonergic drugs including SNRIs.
Manejo clínico
Use with caution; counsel patients on warning signs of serotonin syndrome and seek immediate medical care if symptoms develop.